Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Automated peritoneal dialysis (APD) is increasingly being used because of convenience and remote patient monitoring (RPM) availability. Of the RPM functions, the cycle profile—a time-resolved waveform of inflow, dwell, and drainage—offers a unique approach to detect intracycle abnormalities. Although RPM is associated with reduced hospitalization and improved technique survival, few studies have demonstrated immediate waveform improvements following targeted interventions.
We evaluated three patients undergoing APD with abnormal cycle profiles detected through a cloud-based RPM platform (Sharesource®). Clinical evaluation identified distinct underlying issues.
Case 1: A 70-year-old woman with diabetic nephropathy developed outflow failure shortly after peritoneal dialysis (PD) initiation. RPM revealed markedly prolonged drainage and infusion curves. She was hospitalized, and laparoscopy revealed catheter entrapment by the fimbriae of the fallopian tube. Surgical repositioning restored drainage slope and infusion rate, completing cycles within the programmed timeframe.
Case 2: A 41-year-old man with diabetic nephropathy experienced progressive weight gain and repeated cycle alarms. RPM data indicated progressively extended drainage phases with incomplete emptying. He was hospitalized, and laparoscopic catheter repositioning restored pelvic placement. Post-intervention cycle profiles showed sharply decreased drainage times, complete outflow, and stable ultrafiltration.
Case 3: A 53-year-old man with IgA nephropathy experienced shortened treatment durations. RPM cycle profiles revealed prematurely truncated inflow and drainage curves. Behavioral counseling addressed intentional early termination, normalizing cycle lengths. Subsequent waveforms showed complete inflow and drainage sequences with consistent total treatment duration.
Waveform normalization was observed immediately after intervention. Targeted measures, including surgical correction in hospitalized patients (Cases 1 and 2) and lifestyle modification in an outpatient setting (Case 3), resulted in immediate, objective improvements. Prolonged drainage curves normalized, infusion irregularities resolved, and premature session termination disappeared. Waveform improvements paralleled symptom resolution, with no patient requiring modality switch. Two clinical insights were evident: (1) cycle profiles are sensitive, real-time indicators of dysfunction and recovery, and (2) RPM supports technical troubleshooting and behavioral modification.
This case series demonstrates the novel role of RPM-enabled cycle profile monitoring for APD. By capturing granular inflow and outflow dynamics, RPM provides actionable insights for timely correction of mechanical complications and identification of behavioral nonadherence. To our knowledge, this is the first report documenting immediate normalization of cycle profile waveforms following therapeutic intervention. Broader adoption of cycle profile analysis may enhance treatment quality, patient safety, and personalized PD care. Prospective studies are needed to validate its role as a clinical marker for outcomes in PD.
